keyword
MENU ▼
Read by QxMD icon Read
search

Jardiance

keyword
https://www.readbyqxmd.com/read/27697060/prediction-of-anti-diabetic-drugs-as-dual-inhibitors-against-acetylcholinesterase-and-beta-secretase-a-neuroinformatics-study
#1
Sibhghatulla Shaikh, Syed Mohd Danish Rizvi, Tabinda Suhail, Shazi Shakil, Adel M Abuzenadah, Rukhsar Anis, Deeba Naaz, Mohd Haneef, Adnan Ahmad, Latafat Choudhary
An increasing number of research evidences indicate linkage between type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD); the two most common diseases of aging. In addition, T2DM and AD also share some common pathophysiological features. Therefore, dual therapy that targets both the diseases can be regarded as a beneficial approach. Acetylcholinesterase (AChE) and beta-secretase (BACE) have been considered as potential therapeutic targets for AD. Accordingly, the piece of work presented here describes the binding of anti-diabetic drugs (Jardiance, Suiny and Nesina) with AChE and BACE so as to further investigate connecting bridges concerning the treatment of these two diseases...
October 3, 2016: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/27486640/empagliflozin-jardiance-type-2-diabetes-no-rush-to-use-this-drug
#2
REVIEW
(no author information available yet)
* In early 2016, metformin monotherapy remains the treatment of choice for most patients with type 2 diabetes. There are several alternatives for patients in whom metformin is poorly tolerated or ineffective. However, dapagliflozin and canagiflozin have an unfavourable harm-benefit balance and should not be used to enhance the action of metformin. Empagliflozin is the third glifozin to be authorised in the European Union for the treatment of type 2 diabetes. A randomised, double-blind, placebo-controlled trial of empaglifloznin, in combination with other glucose-lowering drugs, involved 7020 patients with type 2 diabetes, an average glycated haemoglobin (HbA1c) concentration of about 8%, and a history of at least one cardiovascular event...
June 2016: Prescrire International
https://www.readbyqxmd.com/read/27417322/%C3%A2-empagliflozin-diabetes-and-outcomes
#3
(no author information available yet)
The prevalence of type 2 diabetes is rising, and in 2015 more than 5% of adults in the UK were affected by this condition.(1,2) Management of type 2 diabetes includes encouraging lifestyle changes (increased exercise, modification of diet and smoking cessation) alongside the provision of medication to minimise long-term complications and manage blood sugar control while avoiding unwanted effects of drug treatment.(3) Of particular importance, people with type 2 diabetes are at increased risk of cardiovascular disease, and therefore the aims of treatment also include modification of associated risk factors...
July 2016: Drug and Therapeutics Bulletin
https://www.readbyqxmd.com/read/26638450/-empagliflozin-jardiance-nw-sglt2-cotransporter-inhibitor-for-treating-type-2-diabetes
#4
A J Scheen
Empagliflozin is a new inhibitor of sodiumglucose cotransporters type 2 (SGLT2) for the treatment of type 2 diabetes mellitus (T2DM). Its specific action inhibits glucose reabsorption in renal tubules and thus promotes glucosuria. This effect results in a reduction in fasting and postprandial glycaemia and a decrease of glycated haemoglobin (HbA(Ic)), independently of insulin. Furthermore, calorie urinary loss promotes weight reduction and osmotic diuresis lowers arterial blood pressure. The efficacy of empagliflozin increases according to the level of hyperglycaemia but decreases in patients with renal insufficiency...
September 2015: Revue Médicale de Liège
https://www.readbyqxmd.com/read/26629271/jardiance-empagliflozin-an-sglt2-inhibitor-receives-fda-approval-for-the-treatment-of-patients-with-type-2-diabetes
#5
Loretta Fala
No abstract text is available yet for this article.
March 2015: American Health & Drug Benefits
https://www.readbyqxmd.com/read/26045645/empagliflozin-jardiance-a-novel-sglt2-inhibitor-for-the-treatment-of-type-2-diabetes
#6
Uche Anadu Ndefo, Nicole O Anidiobi, Efrah Basheer, Angie T Eaton
Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes.
June 2015: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/25813264/-empagliflozin%C3%A2-the-new-representative-of-sglt2%C3%A2-transporter-inhibitors-for-the-treatment-of-patients-with-diabetes-2%C3%A2-type
#7
Martin Prázný, Jiří Slíva
Empagliflozin is a new medicine used to reduce hyperglycemia in patients with type 2 diabetes. It belongs to the most advanced class of antidiabetic drugs, known as gliflozins, which prevent reabsorption of glucose through inhibiting SGLT2 sodium-glucose cotransporter. Thereby they cause therapeutic glycosuria, thanks to which a loss of approximately 70 g of glucose per day occurs. This not only effects the decrease in glycemia, but also the loss of body mass, since this excreted glucose cannot be used as an energetic substrate...
February 2015: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/25296258/empagliflozin-jardiance-for-diabetes
#8
(no author information available yet)
No abstract text is available yet for this article.
October 13, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/25274537/empagliflozin-a-review-of-its-use-in-patients-with-type-2-diabetes-mellitus
#9
REVIEW
Lesley J Scott
Oral empagliflozin (Jardiance(®)), a sodium glucose cotransporter-2 (SGLT2) inhibitor, is a convenient once-daily treatment for adult patients with type 2 diabetes mellitus. By inhibiting reabsorption of glucose from the proximal tubules in the kidney via inhibition of SGLT2, empagliflozin provides a novel insulin-independent mechanism of lowering blood glucose. In several phase III trials (≤104 weeks' duration; typically 24 weeks' duration) and extension studies (typically ≥76 weeks' treatment), empagliflozin monotherapy or add-on therapy to other antihyperglycaemics, including insulin, improved glycaemic control and reduced bodyweight and systolic blood pressure in adult patients with type 2 diabetes...
October 2014: Drugs
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"